Phase II Study of Preoperative Treatment with External Radiotherapy Plus Panitumumab in Low‐Risk Locally Advanced Rectal Cancer (RaP Study/STAR‐03)

摘要

Background.Treatment with fluoropyrimidines and concomitant long‐course external radiotherapy (RTE) is the standard of care in locally advanced rectal cancer (LARC) preoperative chemoradiation. A randomized phase II study (RaP/STAR‐03) was conducted that aimed to evaluate the activity and safety of the monoclonal antibody anti‐epidermal growth factor receptor panitumumab as a single agent in combination with radiotherapy in low‐risk LARC preoperative treatment.